SHANGHAI, June 1, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the world's leading oncology conferences, the ASCO Annual Meeting serves as a key venue for presenting advances in...
Hence then, the article about hengrui pharma presents more than 90 oncology studies at asco 2026 highlighting progress across multiple tumor types was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types )
Also on site :
- Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
- 2026 ASCO .. Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
- D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC